Insider Selling: Pacira Biosciences Inc (NASDAQ:PCRX) CEO Sells 12,385 Shares of Stock

Pacira Biosciences Inc (NASDAQ:PCRX) CEO David M. Stack sold 12,385 shares of the stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $42.91, for a total transaction of $531,440.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

NASDAQ PCRX opened at $43.49 on Friday. The company has a fifty day simple moving average of $44.00. Pacira Biosciences Inc has a 12-month low of $30.95 and a 12-month high of $55.00. The company has a current ratio of 8.62, a quick ratio of 7.83 and a debt-to-equity ratio of 0.99. The firm has a market cap of $1.80 billion, a P/E ratio of 149.97, a P/E/G ratio of 2.43 and a beta of 1.24.

Pacira Biosciences (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.20. Pacira Biosciences had a return on equity of 6.78% and a net margin of 2.10%. The business had revenue of $91.31 million for the quarter, compared to analysts’ expectations of $92.13 million. During the same period last year, the business earned $0.02 EPS. The business’s revenue was up 22.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Pacira Biosciences Inc will post 0.77 EPS for the current fiscal year.

A number of research analysts recently issued reports on PCRX shares. BMO Capital Markets set a $44.00 price objective on shares of Pacira Biosciences and gave the company a “hold” rating in a report on Friday, March 1st. Cowen reissued a “hold” rating on shares of Pacira Biosciences in a research report on Friday, March 1st. Stifel Nicolaus reissued a “sell” rating and set a $33.00 target price on shares of Pacira Biosciences in a research report on Friday, March 8th. Wedbush reissued an “outperform” rating and set a $85.00 target price on shares of Pacira Biosciences in a research report on Friday, March 8th. Finally, ValuEngine downgraded shares of Pacira Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $54.53.

A number of large investors have recently modified their holdings of PCRX. Amundi Pioneer Asset Management Inc. bought a new position in Pacira Biosciences during the 1st quarter valued at $65,000. Rehmann Capital Advisory Group raised its stake in shares of Pacira Biosciences by 28.5% during the 4th quarter. Rehmann Capital Advisory Group now owns 2,217 shares of the company’s stock worth $95,000 after purchasing an additional 492 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Pacira Biosciences by 22.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,950 shares of the company’s stock worth $127,000 after purchasing an additional 538 shares during the period. First Mercantile Trust Co. bought a new stake in shares of Pacira Biosciences during the 1st quarter worth $142,000. Finally, Quantamental Technologies LLC bought a new stake in shares of Pacira Biosciences during the 1st quarter worth $162,000. Institutional investors and hedge funds own 99.13% of the company’s stock.

About Pacira Biosciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Article: Analyzing a company’s cash flow statement

Insider Buying and Selling by Quarter for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.